It's time for robust immuno-oncology research solutions
Advance your immuno-oncology research with next-generation sequencing tools
Current PD-1 and PD-L1 biomarkers are insufficient for research sample stratification. It’s time for robust immuno-oncology research solutions. Using trusted Ion AmpliSeq™ technology and content selection protocols informed by the Oncomine™ Knowledgebase, we’re bringing the scalability and power of NGS to immuno-oncology.